ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Hawaii » Pulmonary Disease

Top Pulmonary Disease Prescribers in Hawaii

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
NESTOR ISIDRO DEL ROSARIO M.D.

Pulmonary Disease

21,532

$1.95M

794
679 are 65+

2%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 4%

3%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

27%
prescriptions for brand name drugs

Avg: 53%

$90
Average prescription price

Avg: $125

MAGDY METTIAS M.D.

Pulmonary Disease

9,389

$505K

397
282 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

29%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

25%
prescriptions for brand name drugs

Avg: 53%

$54
Average prescription price

Avg: $125

WILLIAM MITCHELL M.D.

Pulmonary Disease

9,052

$549K

413
360 are 65+

5%
patients receiving schedule two controlled substances

Avg: 1%

7%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

27%
prescriptions for brand name drugs

Avg: 53%

$61
Average prescription price

Avg: $125

BENJAMIN ONO MD

Pulmonary Disease

6,165

$608K

349
315 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

3%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

44%
prescriptions for brand name drugs

Avg: 53%

$99
Average prescription price

Avg: $125

KEVIN HARA M.D.

Pulmonary Disease

3,975

$313K

385
333 are 65+

3%
patients receiving schedule two controlled substances

Avg: 1%

4%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

29%
prescriptions for brand name drugs

Avg: 53%

$79
Average prescription price

Avg: $125

STUART SUGIHARA M.D.

Pulmonary Disease

3,004

$475K

394
377 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

61%
prescriptions for brand name drugs

Avg: 53%

$158
Average prescription price

Avg: $125

ELAINE IMOTO MD

Pulmonary Disease

2,316

$746K

274
230 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

58%
prescriptions for brand name drugs

Avg: 53%

$322
Average prescription price

Avg: $125

THOMAS POLLARD DO

Pulmonary Disease

2,254

$495K

234
182 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

51%
prescriptions for brand name drugs

Avg: 53%

$220
Average prescription price

Avg: $125

ERNIE YIM M.D.

Pulmonary Disease

2,069

$234K

171
159 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

13%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

46%
prescriptions for brand name drugs

Avg: 53%

$113
Average prescription price

Avg: $125

ALVIN FURUIKE M.D.

Pulmonary Disease

2,034

$403K

263
237 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

1%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

63%
prescriptions for brand name drugs

Avg: 53%

$198
Average prescription price

Avg: $125

GEORGE DRUGER M.D.

Pulmonary Disease

1,936

$230K

230
203 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

6%
patients receiving schedule three controlled substances

Avg: 4%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

43%
prescriptions for brand name drugs

Avg: 53%

$119
Average prescription price

Avg: $125

TAD JACKSON MD

Pulmonary Disease

1,416

$333K

193
155 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

62%
prescriptions for brand name drugs

Avg: 53%

$235
Average prescription price

Avg: $125

WARREN TAMAMOTO MD

Pulmonary Disease

1,301

$521K

332
295 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

70%
prescriptions for brand name drugs

Avg: 53%

$400
Average prescription price

Avg: $125

ROGER YIM M.D.

Pulmonary Disease

1,118

$463K

206
170 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

75%
prescriptions for brand name drugs

Avg: 53%

$414
Average prescription price

Avg: $125

SHANON MAKEKAU MD

Pulmonary Disease

870

$245K

224
201 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

65%
prescriptions for brand name drugs

Avg: 53%

$282
Average prescription price

Avg: $125

JOHN BEAMIS MD

Pulmonary Disease

410

$354K

116
109 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

65%
prescriptions for brand name drugs

Avg: 53%

$862
Average prescription price

Avg: $125

PETER MUTHARD M.D.

Pulmonary Disease

322

$189K

60
47 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

73%
prescriptions for brand name drugs

Avg: 53%

$587
Average prescription price

Avg: $125

JAMIL SULIEMAN M.D.

Pulmonary Disease

148

$29.4K

32
26 are 65+

0%
patients receiving schedule two controlled substances

Avg: 1%

0%
patients receiving schedule three controlled substances

Avg: 4%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 1%

79%
prescriptions for brand name drugs

Avg: 53%

$199
Average prescription price

Avg: $125

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank